| General population (n=101) | GnRH agonist protocol (n=60) | GnRH antagonist protocol (n=41) | P |
---|---|---|---|---|
Age (years) | 34.1±5.1 (21–39) | 34.1±5.4 (21–39) | 34.1±4.7 (26–39) | ns |
AMH (ng/ml) | 1.8±1.8(0.01-9.6) | 1.5±1.3 (0.01-8.2) | 2.3±2.2 (0.01-9.6) | ns |
AFC (n) (2–9 mm) | 12.5±6.2 (2–34) | 11.8±5.3 (2–34) | 13.6±7.1 (4–28) | ns |
ORPI | 1.0±1.5(0–8.8) | 0.7±1.2(0–8.8) | 1.3±1.8(0–7.6) | ns |
BMI | 24.6±4.1 | 24.0±4.1 | 25.6±3.8 | ns |
Tobacco use | 4% (4/101) | 3.3% (2/60) | 4.9% (2/41) | ns |
Regular alcohol use | 1% (1/101) | 1.7% (1/60) | 0/41 | ns |
Time of infertility (years) | 4.9±3.3 | 5.1±3.6 | 4.1±2.7 | ns |
Aetiology (%) | Â | Â | Â | ns |
-Male | 35.6% (36/101) | 41.6% (25/60) | 26.8% (11/41) | Â |
-Idiopathic | 25.7% (26/101) | 20% (12/60) | 34.1% (14/41) | Â |
-Tuboperitoneal | 17.8% (18/101) | 16.7% (10/60) | 19.5% (8/41) | Â |
-Endometriosis | 12.9% (13/101) | 15% (9/60) | 9.8% (4/41) | Â |
-Tuboperitoneal+endometriosis | 4% (4/101) | 3.3% (2/60) | 4.9% (2/41) | Â |
-Male+endometriosis | 3% (3/101) | 1.7% (1/60) | 4.9% (2/41) | Â |
-Male+tuboperitoneal | 1% (1/101) | 1.7% (1/60) | 0.0% (0/41) | Â |
Infertility | Â | Â | Â | ns |
-Primary | 78.2% (79/101) | 81.7% (49/60) | 73.2% (30/41) | Â |
-Secondary | 21.8% (22/101) | 18.3% (11/60) | 26.8% (11/41) | Â |
Total dose FSH (UI) | 1956±804 | 2136±774 | 1692±782 | ns |
Total dose LH (UI) | 982±351 | 1035±322 | 903±380 | ns |
Time of stimulation (days) | 10.2±2.1 | 10.6±2.1 | 9.5±1.9 | ns |
Follicles (n) (hCG day) | Â | Â | Â | Â |
-≥10 mm | 12.8±8.6 | 12.8±7.3 | 12.8±10.4 | ns |
-≥16 mm | 5.7±3.5 | 6.2±3.4 | 4.9±3.5 | ns |
-≥18 mm | 3.8±2.6 | 4.2±2.2 | 3.3±2.9 | ns |
Retrieved oocytes | Â | Â | Â | Â |
-Total | 9.7±7.1 | 9.7±6.0 | 9.6±8.4 | ns |
-Metaphase II stage | 6.9±5.2 | 7.1±4.6 | 6.6±6.0 | ns |
-Metaphase I stage | 1.3±1.8 | 1.2±1.6 | 1.5±2.1 | ns |
-Germinal vesicle stage | 0.8±1.1 | 0.8±1.2 | 0.7±1.0 | ns |
Clinical pregnancy rate | 32.7% (33/101) | 31.2% (19/60) | 34.1% (14/41) | ns |